Lupus Landmark Study: A Prospective Registry and Biorepository (NCT05934149)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (25 Sites)

• University of Alabama at Birmingham — Birmingham, Alabama
• University of Arizona — Tucson, Arizona
• Wallace Rheumatic Studies Center — Beverly Hills, California
• UCLA — Los Angeles, California
• Georgetown University — Washington D.C., District of Columbia
• University of Miami — Miami, Florida
• Emory University — Atlanta, Georgia
• University of Chicago — Chicago, Illinois
• Brigham and Women's Hospital — Boston, Massachusetts
• University of Massachusetts Memorial Health — Worcester, Massachusetts
• Washington University — St Louis, Missouri
• The Feinstein Institutes for Medical Research — Manhasset, New York
• Columbia University Medical Center — New York, New York
• Northwell Health — New York, New York
• SUNY Upstate — Syracuse, New York
• UNC Chapel Hill — Chapel Hill, North Carolina
• The MetroHealth System — Cleveland, Ohio
• Vanderbilt University Medical Center — Nashville, Tennessee
• UT Southwestern Medical Center — Dallas, Texas
• University of Calgary — Calgary, Alberta
• University of Alberta Hospital — Edmonton, Alberta
• University of Manitoba — Winnipeg, Manitoba
• University Health Network/Toronto Western Hospital — Toronto, Ontario
• McGill University Health Centre — Montreal, Quebec
• CHU de Québec - Université Laval — Québec, Quebec

📞 Contact the Study Coordinator

Phone: (646) 884-6084

Email: lupusnexus@lupusresearch.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Systemic Lupus Erythematosus (SLE)

• Descartes-08 for Patients With Systemic Lupus Erythematosus — Oceanside, California
• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease — Los Angeles, California
• A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 — Farmington, Connecticut
• Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus — Bethesda, Maryland
• A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants — Mesa, Arizona
• Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires — Bethesda, Maryland

Explore by condition: All Systemic Lupus Erythematosus (SLE) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.